{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:00:47Z","timestamp":1776445247477,"version":"3.51.2"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.farma.2024.04.012","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T19:54:03Z","timestamp":1718740443000},"page":"T204-T211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["[Translated article] Perceived quality of life in patients with psoriasis treated with interleukin 17 or 23 inhibitors"],"prefix":"10.1016","volume":"48","author":[{"given":"B\u00e1rbara","family":"Anguita-Montenegro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera Luc\u00eda Areas-del","family":"\u00c1guila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Palacios-Moya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Garc\u00eda-Arpa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Prado","family":"S\u00e1nchez-Caminero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Luque-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.farma.2024.04.012_bb0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ad.2013.12.008","article-title":"Prevalencia de la psoriasis en Espa\u00f1a en la era de los agentes biol\u00f3gicos","volume":"105","author":"Ferrandiz","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.farma.2024.04.012_bb0010","author":"AEMPS"},{"issue":"19","key":"10.1016\/j.farma.2024.04.012_bb0015","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation and treatment of psoriasis. A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.farma.2024.04.012_bb0020","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ad.2013.02.018","article-title":"Impacto en la calidad de vida relacionada con la salud de pacientes con psoriasis activa y estable","volume":"104","author":"Daud\u00e9n","year":"2013","journal-title":"Estudio PSO-LIFE. Actas Dermo-Sifiliogr\u00e1ficas."},{"key":"10.1016\/j.farma.2024.04.012_bb0025","author":"Acci\u00f3n Psoriasis"},{"issue":"3","key":"10.1016\/j.farma.2024.04.012_bb0030","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/jdv.12106","article-title":"Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies","volume":"28","author":"Mattei","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.farma.2024.04.012_bb0035","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ajd.12353","article-title":"Durable dermatology life quality index improvements in patients on biologics associated with psoriasis area and severity index: a longitudinal study","volume":"57","author":"Chaptini","year":"2016","journal-title":"Australas J Dermatol."},{"key":"10.1016\/j.farma.2024.04.012_bb0040","first-page":"54","article-title":"Calidad de vida de pacientes con psoriasis en un hospital de tercer nivel. Comunicaci\u00f3n de 59 casos","author":"Cort\u00e9s","year":"2010","journal-title":"Dermatolog\u00eda Rev. Mex."},{"key":"10.1016\/j.farma.2024.04.012_bb0045","first-page":"102357","article-title":"Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literatura","author":"Belinch\u00f3n","year":"2016","journal-title":"Patient Pref Adher."},{"issue":"6","key":"10.1016\/j.farma.2024.04.012_bb0050","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/jcm11061506","article-title":"Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis","volume":"11","author":"Piragine","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.farma.2024.04.012_bb0055","author":"Herdman"},{"issue":"7","key":"10.1016\/j.farma.2024.04.012_bb0060","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ad.2019.02.009","article-title":"Instrumentos para la valoraci\u00f3n de los resultados percibidos por el paciente con psoriasis en Espa\u00f1a: revisi\u00f3n sistem\u00e1tica de la literatura","volume":"110","author":"Liz\u00e1n","year":"2019","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas."},{"issue":"2","key":"10.1016\/j.farma.2024.04.012_bb0065","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.det.2011.11.002","article-title":"A review of the use of the dermatology life quality index as a criterion in clinical guidelines and health technology assessments in psoriasis and chronic hand eczema","volume":"30","author":"Basra","year":"2012","journal-title":"Dermatol Clin."},{"issue":"3","key":"10.1016\/j.farma.2024.04.012_bb0070","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ad.2021.10.003","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermo-Sifiliogr"},{"issue":"1 Suppl","key":"10.1016\/j.farma.2024.04.012_bb0075","first-page":"2","article-title":"The national cholesterol education program adult treatment panel III guidelines","volume":"9","author":"Lipsy","year":"2003","journal-title":"J Manag Care Pharm."},{"issue":"11","key":"10.1016\/j.farma.2024.04.012_bb0080","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris- Part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.farma.2024.04.012_bb0085","series-title":"VI Congreso Nacional de Psoriasis","article-title":"P-30 Resultados percibidos por el paciente en una cohorte espa\u00f1ola de pacientes con psoriasis moderada-grave tratados con secukinumab","author":"Chicharro","year":"2021"},{"issue":"12","key":"10.1016\/j.farma.2024.04.012_bb0090","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1111\/1346-8138.16128","article-title":"Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial","volume":"48","author":"Gerdes","year":"2021","journal-title":"J Dermatol."},{"issue":"4","key":"10.1016\/j.farma.2024.04.012_bb0095","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/bjd.19325","article-title":"Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis","volume":"183","author":"Mahil","year":"2020","journal-title":"Br J Dermatol."},{"issue":"5","key":"10.1016\/j.farma.2024.04.012_bb0100","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev."},{"issue":"8","key":"10.1016\/j.farma.2024.04.012_bb0105","doi-asserted-by":"crossref","first-page":"854","DOI":"10.36849\/JDD.66791","article-title":"Onset of plaque psoriasis treatment responses with anti-IL-17\/IL-23 biologic therapies","volume":"21","author":"Fried","year":"2022","journal-title":"J Drugs Dermatol."},{"key":"10.1016\/j.farma.2024.04.012_bb0110","author":"AEMPS"},{"key":"10.1016\/j.farma.2024.04.012_bb0115","author":"AEMPS"},{"key":"10.1016\/j.farma.2024.04.012_bb0120","author":"AEMPS"},{"key":"10.1016\/j.farma.2024.04.012_bb0125","author":"AEMPS"},{"issue":"1","key":"10.1016\/j.farma.2024.04.012_bb0130","first-page":"27","article-title":"Health-related quality of life in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis treated with certolizumab pegol","volume":"46","author":"Sarobe","year":"2022","journal-title":"Farm Hosp."},{"issue":"8","key":"10.1016\/j.farma.2024.04.012_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15622","article-title":"Sociodemographic, clinical and therapeutic factors as predictors of life quality impairment in psoriasis: a cross-sectional study in Italy","volume":"35","author":"Scala","year":"2022","journal-title":"Dermatol Ther."},{"issue":"8","key":"10.1016\/j.farma.2024.04.012_bb0140","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/jdv.16684","article-title":"Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian evidence-based treatment advice in psoriasis; part 1)","volume":"34","author":"Lambert","year":"2020","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"6","key":"10.1016\/j.farma.2024.04.012_bb0145","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ad.2022.01.024","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermo-Sifiliogr"},{"issue":"4","key":"10.1016\/j.farma.2024.04.012_bb0150","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s13555-021-00564-2","article-title":"Correlation between change in psoriasis area and severity index and dermatology life quality index in patients with psoriasis: pooled analysis from four phase 3 clinical trials of secukinumab","volume":"11","author":"Houghton","year":"2021","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T00:40:17Z","timestamp":1726360817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1130634324000692"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.04.012","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Translated article] Perceived quality of life in patients with psoriasis treated with interleukin 17 or 23 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.01.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}